Compare · BLRX vs LLY
BLRX vs LLY
Side-by-side comparison of BioLineRx Ltd. (BLRX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLRX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 93281.0x BLRX ($12.4M).
- Over the past year, BLRX is down 22.5% and LLY is up 67.6% - LLY leads by 90.2 points.
- LLY has been more active in the news (17 items in the past 4 weeks vs 2 for BLRX).
- LLY has more recent analyst coverage (25 ratings vs 0 for BLRX).
- Company
- BioLineRx Ltd.
- Eli Lilly and Company
- Price
- $2.82+3.30%
- $1233.40-1.12%
- Market cap
- $12.4M
- $1.16T
- 1M return
- -1.40%
- +3.00%
- 1Y return
- -22.53%
- +67.64%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 17
- Recent ratings
- 0
- 25
BioLineRx Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest BLRX
- BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
- SEC Form 6-K filed by BioLineRx Ltd.
- BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
- SEC Form 6-K filed by BioLineRx Ltd.
- BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
- SEC Form 6-K filed by BioLineRx Ltd.
- BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 6-K filed by BioLineRx Ltd.
- BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- BioLineRx to Report First Quarter 2026 Results on May 27, 2026
Latest LLY
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market